976-65-8

Upstream product

• 132862-06-7 N-(1-benzylpiperidin-4-yl)phenylacetamide 
• 51448-56-7 4-amino-1-(2-phenylethyl)-piperidine 
• 103-80-0 phenylacetyl chloride 
• 103-63-9 1-phenyl-2-bromoethane 
• 75484-47-8 4-phenylacetamidopiperidine 

Downstream Products

• 28456-25-9 phenethyl-(1-phenethyl-piperidin-4-yl)-amine 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of N-(1-benzylpiperidin-4-yl)arylacetamide analogues as potent σ1receptor ligands

A series of N-(1-benzylpiperidin-4-yl)arylacetamides were synthesized and evaluated for their binding properties for σ1 and σ2 receptors. In agreement with previously reported σ1/σ2 receptor binding data for N-(1-benzylpiperidin-4-yl)phenylacetamide, all of the N-(1-benzylpiperidin-4-yl)arylacetamide compounds reported below displayed higher affinity for σ1 vs σ1 receptors. Replacement of the phenyl ring of the phenylacetamide moiety with a thiophene, naphthyl, or indole aromatic ring had no significant effect on the σ1 receptor affinity. Replacement of the phenyl ring with an imidazole or pyridyl aromatic ring resulted in a >60-fold loss in affinity for σ1 receptors and no significant binding affinity for σ2 receptors. Substitution on the aromatic ring of the benzyl group showed a similar or slightly decreased affinity for σ1 receptors. Substitution on the aromatic rings of both the phenylacetamide moiety and the benzyl group with a halogen resulted in a similar affinity for σ1 receptors and a significantly increased affinity for σ2 receptors. Comparative molecular field analysis revealed that electrostatic properties of the substituents in the phenylacetamide aromatic ring strongly influenced binding to σ1 receptors. Compounds 1, 10, 18, 22, 37, and 40 showed the highest selectivity for σ1 receptors with Ki (σ2) to Ki (σ1) ratios of 100, >92, >122, 77, 74, and 80, respectively. In agreement with previously reported results, the phenylacetamide analogues had no binding affinity for dopamine receptors (D2/D3).

Structure-activity studies of fentanyl

The preparation of analogues of fentanyl with para substituents in the anilino aromatic ring, anilino nitrogen separated from phenyl by methylene or bimethylene, and phenacyl replacing propionyl as the N-acyl substituent is reported. Although all para sub

Pharmaceutical compositions and methods of treating hypertension

Pharmaceutical compositions containing a group of heterocyclic compounds and their use in treatment of disorders and diseases of the cardiovascular system and/or in the treatment of superficial and deep allergic phenomena is described. These compounds used in the composition and/or methods are piperidine compounds linked by the nitrogen atom to a substituted or unsubstituted cycloalkyl, aryl or heterocyclic radical through the intermediary of a group selected from a lower-alkylene radical, a monoketo lower-alkylene radical or a hydroxy-lower-alkylene radical, or a bivalent radical of the formula --NH.CO.(CH2)n -- where n is 1, 2 or 3, STR1 or --0-(lower-alkylene)--. The piperidine ring is further substituted by an acylamino residue.

HETEROCYCLIC COMPOUNDS

A group of heterocyclic compounds useful in the treatment of disorders and diseases of the cardiovascular system and/or in the treatment of superficial and deep allergic phenomena is described. These compounds are piperidine compounds linked by the nitrogen atom to a substituted or unsubstituted phenyl radical through the intermediary of a group selected from a lower-alkylene radical, a mono-keto lower alkylene radical or a hydroxy-lower-alkylene radical, or a bivalent radical of the formula EQU1 or--O--(lower-alkylene)-. The piperidine rings are further substituted by a benzamido, substituted benzamido or cyclohexylcarboxamido residue.